Business
ViaDerma, Inc. Begins Consumer Testing on its Topical Antibiotic in the Philippines Due to Country Wide Interest from Distributors as it Eyes Huge Market for Several New Follow-on Products with Registration Numbers from the FDA Soon to Follow
ViaDerma, Inc. Begins Consumer Testing on its Topical Antibiotic in the Philippines Due to Country Wide Interest from Distributors as it Eyes Huge Market for Several New Follow-on Products with Registration Numbers from the FDA Soon to Follow.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. Begins Consumer Testing on its Topical Antibiotic in the Philippines Due to Country Wide Interest from Distributors as it Eyes Huge Market for Several New Follow-on Products with Registration Numbers from the FDA Soon to Follow\n\nViaDerma, Inc. Begins Consumer Testing on its Topical Antibiotic in the Philippines Due to Country Wide Interest from Distributors as it Eyes Huge Market for Several New Follow-on Products with Registration Numbers from the FDA Soon to Follow\n\n LOS ANGELES, CA--(Marketwired - June 15, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has commenced \"Consumer Test Studies\" of its tetracycline based topical antibiotic in the Philippines. The product has been well received by Doctors and Distributors throughout the country. The Distributors are also interested in ViaDerma's six follow-on products which are expecting FDA registration numbers throughout the rest of 2017. The Philippines is well acquainted with pharmaceutical manufacturing for companies such as GlaxoSmithKline, Novartis and Sanofi, which are among the largest foreign pharmaceutical companies doing business in the Philippines. Among domestic drug companies, United Laboratories, Pascual Laboratories, GC International and Natrapharm are the largest. ViaDerma's topical antibiotic is now ready for sale. The antibiotics market is expected to reach USD $57.0 billion by 2024, according to the new report by Grand View Research, Inc. Rising prevalence of infectious diseases especially in developing regions such as Asia Pacific and MEA is anticipated to contribute towards market growth. ViaDerma sees the environment for its product line as a natural fit as the generics and over the counter segments have become increasingly important in the Philippines. ViaDerma, Inc. has completed the quality control and approved labeling for the product in the USA and will begin distribution of the drug later this month. The Company's President, Dr. Christopher Otiko said, \"We have seen increased interest in our products due to the need in this part of the world. The closer we are to distribution it seems we are pleasantly surprised by Distributors' inquiries for the medication. Our product manufacturer will be able to manufacture most o...